This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
LGD-4033 (Ligandrol)
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW HIGH
HPG-axis suppression in still-developing 20yo endocrine + brain-development concerns + documented hepatotoxicity case reports + FDA prohibited + research-chem product identity questionable. Nothing about this user's stated priorities (brain #1, MMA performance) is meaningfully advanced by a body-comp anabolic. Verdict would change only at age 30+ with bloodwork-supported HPG recovery plan, post-cycle therapy access, and verified product COA — and even then the evidence/risk ratio is poor vs alternatives.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-AT- | HPG-axis suppression at this age is a direct hit on still-finalizing endocrine development. Brain-development at 20 is not "done" — prefrontal cortex maturation continues to ~25 and androgen signaling participates in CNS development. Hepatotoxicity case reports are concentrated in this exact demographic. Body-composition gains are not on the user's stated priority list (#1 brain, #2 MMA performance, #3 longevity, #4 recovery — aesthetic/mass explicitly downstream). Untested status removes WADA argument but does not remove physiology. |
30-50, executive maintenance | WATCH-LIST | → still SKIP-FOR-NOW for most; only consider if hypogonadal with bloodwork support and even then enclomiphene or TRT under endocrinologist supervision is preferred over SARMs. |
50+, mild cognitive decline | N | a cognitive-decline tool. Off-target. |
Anxiety-prone | SKIP | mood disturbance + cycle-end depression risk. |
High athletic load, tested status | SKIP-PERMANENT | WADA Prohibited. |
Sleep-disordered | O | (no sleep relevance). |
Recovery-focused (post-injury, post-illness) | WATCH-LIST | narrowly — Phase 2 trials targeted hip-fracture recovery, but ostarine (better safety profile) or proper TRT are preferred clinical tools. |
Strength/anabolic-focused, age 25+ with full HPG bloodwork + PCT plan | OPTIONAL-ADD | even here the hepatotoxicity tail risk and product-identity risk make it a poor risk-adjusted choice vs alternatives (TRT under physician care, enclomiphene, or simply not using). |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-AT-
HPG-axis suppression at this age is a direct hit on still-finalizing endocrine development. Brain-development at 20 is not "done" — prefrontal cortex maturation continues to ~25 and androgen signaling participates in CNS development. Hepatotoxicity case reports are concentrated in this exact demographic. Body-composition gains are not on the user's stated priority list (#1 brain, #2 MMA performance, #3 longevity, #4 recovery — aesthetic/mass explicitly downstream). Untested status removes WADA argument but does not remove physiology.
- 30-50, executive maintenanceWATCH-LIST
→ still SKIP-FOR-NOW for most; only consider if hypogonadal with bloodwork support and even then enclomiphene or TRT under endocrinologist supervision is preferred over SARMs.
- 50+, mild cognitive declineN
a cognitive-decline tool. Off-target.
- Anxiety-proneSKIP
mood disturbance + cycle-end depression risk.
- High athletic load, tested statusSKIP-PERMANENT
WADA Prohibited.
- Sleep-disorderedO
(no sleep relevance).
- Recovery-focused (post-injury, post-illness)WATCH-LIST
narrowly — Phase 2 trials targeted hip-fracture recovery, but ostarine (better safety profile) or proper TRT are preferred clinical tools.
- Strength/anabolic-focused, age 25+ with full HPG bloodwork + PCT planOPTIONAL-ADD
even here the hepatotoxicity tail risk and product-identity risk make it a poor risk-adjusted choice vs alternatives (TRT under physician care, enclomiphene, or simply not using).
▸ Subjective experience (deep)
Per user reports (forums, podcast interviews, case reports):
- Onset: Body-comp changes appear by week 2-3 (water + early lean mass).
- Peak: Weeks 4-8 — reported strength bump, easier recomposition, slight aggression/drive uptick.
- Cycle-end: Libido drop, mild lethargy, "flat" mood, sometimes depressive symptoms as endogenous testosterone bottoms out. Erectile function commonly affected.
- Recovery: Weeks to months for natural test to return; many users run a SERM PCT (enclomiphene 12.5-25 mg/day or clomid 25-50 mg/day for 4-6 weeks) to accelerate. Some users report incomplete recovery on repeat cycles.
- Highly variable because (a) research-chem product identity is unreliable and (b) users frequently stack with other SARMs or compounds.
▸ Tolerance + cycling deep dive
- Tolerance buildup: Not classical pharmacological tolerance — issue is HPG suppression, which forces cycling rather than continuous use.
- Recommended cycle (research-chem community): 8 weeks on, 4-6 weeks PCT, then 8+ weeks fully off before considering another cycle.
- Reset protocol: SERM PCT (enclomiphene/clomid/tamoxifen). Bloodwork-confirmed return to baseline LH/FSH/testosterone before any subsequent cycle. Many never fully recover on repeat cycling.
▸ Stacking deep dive
Synergistic with
(Documented for context. Stacking SARMs amplifies suppression and hepatotoxicity risk and is not recommended.)
- enclomiphene: Used as PCT to restart HPG axis post-cycle — selective ER antagonist at hypothalamus, drives LH/FSH back up.
- Creatine, protein: Standard anabolic supports; pharmacologically unrelated, no interaction.
Avoid stacking with
- ostarine: Stacking SARMs compounds HPG suppression and hepatotoxicity — not additive in benefit, multiplicative in risk.
- rad-140: Same — RAD-140 is more suppressive than LGD; stacking is the worst-of-both.
- Other 17α-alkylated oral anabolics (winstrol, anavar, dianabol): Hepatotoxic stacking.
- Acetaminophen/paracetamol regular use: Liver burden compounding.
- Heavy alcohol: Liver burden compounding (a user in this archetype is zero-alcohol — non-issue, but flagged generically).
- Statins: Liver enzyme monitoring becomes confounded.
Neutral / safe co-administration
- Most of the user's V stack stack (DHA, magnesium, citicoline, NAC, PS, curcumin, rhodiola, theanine, glycine, D3+K2, beta-alanine, vitamin C) does not interact pharmacodynamically. NAC and curcumin are mildly hepatoprotective, which is incidental — does not justify the risk.
▸ Drug interactions deep dive
- CYP3A4: LGD-4033 is metabolized substantially by CYP3A4; strong inducers (rifampin, St John's wort) reduce exposure, strong inhibitors (ketoconazole, grapefruit, ritonavir) increase exposure and hepatotoxicity risk.
- Warfarin/anticoagulants: Theoretical interaction via hepatic enzyme effects; monitor INR.
- Insulin/glucose-lowering: Anabolic agents can modestly improve insulin sensitivity — monitor if diabetic.
- No documented interactions with modafinil, racetams, or peptides in the user's V stack plan, but co-administration data is sparse.
▸ Pharmacogenomics
- CYP3A4/3A5 polymorphisms affect exposure — fast metabolizers may need higher doses (and accept higher metabolite burden); slow metabolizers face elevated AUC and hepatotoxicity risk.
- AR CAG repeat length modulates androgen sensitivity — shorter repeats = higher sensitivity to anabolic AND suppressive effects.
- HSD3B1 variant alters androgen metabolism — relevant for prostate concerns.
- the user's 23andMe results (June 2026 window) will provide CYP3A4/3A5 and AR CAG data — but this does not change the SKIP verdict, since suppression is mechanism-intrinsic.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research-chem | Various (Chemyo, Sports Technology Labs, Umbrella Labs, etc.) | $30-100 / 30 mL bottle (10 mg/mL liquid) or 60-90 caps | Low-Medium | "For research only" labeling. COA quality varies widely. Independent third-party testing (e.g., via SARMs.io community) regularly finds underdosed, overdosed, or substituted products. |
| FDA-approved Rx | None | N/A | N/A | No approved indication in any country. Viking's VK5211 program is in trials only. |
| Gray-market international | Various | Variable | Low | Customs seizure risk; product identity questionable. |
Sourcing assessment: Even if SKIP verdict were lifted, product identity is the largest uncontrolled risk. Multiple FDA warning letters (2017, 2021) cite products labeled as LGD-4033 actually containing other SARMs, prohormones, or contaminants.
▸ Biomarkers to track (deep)
(Hypothetical — not recommending use.)
- Baseline (before starting): Total testosterone, free testosterone, SHBG, LH, FSH, estradiol (sensitive assay), full lipid panel, CMP including ALT/AST/GGT/total bilirubin/albumin, CBC with hematocrit, PSA, fasting glucose + HbA1c.
- During use: ALT/AST/GGT/bilirubin every 2 weeks; lipid panel at week 4 and week 8; testosterone/LH/FSH at week 4 and week 8.
- Post-cycle: Weekly LH/FSH/total + free testosterone until baseline restored; lipid panel at PCT week 4 and again 4 weeks post-PCT; ALT/AST 4 weeks post-PCT.
▸ Controversies / open debates Live debate
- "Selectivity" claim vs reality: Marketing positions SARMs as androgenic-side-effect-free; clinical data shows AR signaling in hypothalamus and liver is unavoidable. Selectivity is graded, not binary.
- Hepatotoxicity — drug effect vs product contamination: Forum users argue cases are due to bad research-chem products, not LGD itself. LiverTox and JAMA reviewers note the pattern is consistent enough across cases to suggest the parent compound contributes.
- Recovery completeness: Forum lore says "easy recovery with PCT"; clinical case reports include young men with persistent hypogonadism after repeat cycles. Truth probably lies in dose × duration × individual susceptibility.
- Phase 2 (Viking VK5211) trial signal: Hip-fracture muscle-wasting trial showed statistically significant lean-mass gain. Whether this translates to a meaningful clinical product remains undetermined — Viking's pipeline has been intermittent.
▸ Verdict change log
- 2026-05-05 — Initial verdict: SKIP-AT-20 HIGH. Combination of HPG-axis suppression in developing 20yo + hepatotoxicity case reports + brain-development concerns + FDA prohibited + research-chem product identity risk + body-comp goal not on the user's priority list. Verdict would shift only at age 30+, with bloodwork-supported recovery plan, COA-verified product, and a stronger justification than aesthetics.
▸ Open questions / gaps Open
- Long-term (>1 year, multi-cycle) HPG recovery data in healthy young men — does not exist in controlled form.
- True hepatotoxicity incidence rate at therapeutic dose using verified-pure product — unanswerable while sourcing is research-chem only.
- AR CAG repeat × LGD response — would refine individual dose-response but does not change suppression mechanism.
- Whether Viking VK5211 reaches FDA approval and at what indication — would change sourcing landscape but not the SKIP-at-20 logic.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.